Research Article
ViewLux™ Microplate Imager for Metabolite Profiling: Validation and Applications in Drug Development
Julien Bourgailh1, Maxime Garnier1, Robert Nufer1, Hans Pirard2, Markus Walles1* and Piet Swart11Novartis Pharma AG, Novartis Institutes for Biomedical Research, Drug Metabolism and Pharmacokinetics (JB, MG, RN, MW and PS), Basel, Switzerland
2Perkin Elmer (HP), Inc. Waltham, USA
- *Corresponding Author:
- Dr. Markus Walles
Novartis Pharma AG, Novartis Institutes for Biomedical Research
Drug Metabolism and Pharmacokinetics, Fabrikstrasse 14
1.02, CH-4002 Basel, Switzerland
E-mail: markus.walles@novartis.com
Received date: February 26, 2014; Accepted date: March 26, 2014; Published date: March 28, 2014
Citation: Bourgailh J, Garnier M, Nufer R, Pirard H, Walles M, et al. (2014) ViewLux™ Microplate Imager for Metabolite Profiling: Validation and Applications in Drug Development. J Anal Bioanal Tech 5:185. doi: 10.4172/2155-9872.1000185
Copyright: © 2014 Bourgailh J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Generation of early information on metabolic pathways, metabolite structures and their systemic exposure is a highly time consuming activity during the drug development process. Since these data have become of higher interest for the health authorities, efforts have been made to provide results as early as possible. ViewLux UltraHTS Microplate Imager is an instrument originally designed for high throughput in biological assays requiring luminescence, absorbance or fluorescence detections. In this work, we evaluate the capability of the new generation of the instrument for both 14C and 3H detection. We discuss data processing of the Viewlux, especially the background subtraction in comparison to conventional TopCount® instruments, as this has an impact on the limit of detection for samples containing low amounts of radioactivity like samples originating from ADME studies. We demonstrate that the limit of detection can be lowered by prolonging the exposure time for 3H labeled compounds up to 2 h. We validated the ViewLux for our metabolite profiling applications (in vitro and in vivo ADME samples) in early drug development using UPLC followed by fraction collection in 384 well plates and demonstrated for our applications that limits of detection of 2.2 and 24 dpm/well for 14C and 3H, respectively could be reached and that the throughput could be increased by at least two fold compared to conventional Topcount detection. We also demonstrate in this work how endogenous interferences resulting in false positive peaks in samples containing low amounts of radioactivity can be overcome by using a customized light filter.
